Physician profile
Gregg Pearson
NPI 1083645972
$9,514.55
in general payments reported to CMS, 2019-2025
57 companies · $996 in 2025
The $996 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $1,260 · 2021: $1,905 · 2022: $1,380 · 2023: $1,474 · 2024: $1,425 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,876 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,875.78 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,801.47 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,610.79 | 2019-2025 | |
| Lilly USA, LLC | $615.38 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $519.51 | 2019-2025 | |
| Glaxosmithkline, LLC. | $499.60 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $462.79 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.10 | 2019-2025 | Xifaxan |
| Amgen INC. | $362.40 | 2019-2022 | |
| Amarin Pharma, INC. | $283.03 | 2019-2022 | |
| Novo Nordisk INC | $262.03 | 2020-2023 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $248.76 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Sanofi-Aventis U.S. LLC | $243.03 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $182.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.24 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $161.23 | 2022-2025 | Caplyta |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregg Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.